SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is experiencing an extraordinary surge, driven by a recent 13D filing indicating a single shareholder now owns a substantial portion of the company's shares. This has dramatically reduced the public float, leading to intense community speculation about a potential short squeeze and drawing comparisons to past high-volatility low-float runners. Traders are actively discussing the extreme scarcity of available shares, fueling significant momentum and robust buying interest in anticipation of continued upward movement.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending after its Investor Day, where the company announced significantly raised revenue guidance for a future fiscal year, reported strong preliminary results, and highlighted a substantial increase in its cash balance and backlog. The community is actively discussing these updates, with many bulls emphasizing the company's robust fundamentals and anticipated growth in the defense and drone sectors. However, others express caution, citing a rich valuation and perceived market dynamics that may be currently influencing the stock's movement.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market attention driven by recent compelling clinical trial data for its ANKTIVA treatment, demonstrating impressive complete response rates and durability in bladder cancer, coupled with a notable Saudi Arabian approval for lung cancer. The community is actively discussing a potential massive short squeeze, fueled by exceptionally high trading volume and a strong belief in the company's transformative potential in global cancer treatment. Investors are eyeing its long-term pipeline and the possibility of broader regulatory approvals expanding its market significantly.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd ($SUGP) is trending due to widespread community discussion focused on its ultra-low share float and significant short interest, sparking intense speculation about a potential short squeeze. Traders are actively drawing comparisons to past high-volatility stocks, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a major talking point after a significant analyst upgrade to a Buy rating with a raised price target, intensifying community speculation about an upcoming AI deal. Discussion centers on the company's strategic advantage in power capacity for AI infrastructure, a critical bottleneck in the booming sector. While many anticipate substantial growth from its Neo-Cloud transition, some observers remain wary of valuation and potential market dynamics.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is surging due to robust early demand for its new oral Wegovy pill and the UK's approval of a higher injectable dose, reinforcing its competitive edge. With a key rival's oral GLP-1 pill facing an FDA delay, the community is enthusiastically discussing NVO's strengthened market position and potential for substantial growth in the obesity treatment sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as community discussion heats up over recent college sports betting scandals and the evolving landscape of prediction markets, creating market volatility. This comes despite notable analyst upgrades and significant institutional buying, leading to a split in investor sentiment. Many are capitalizing on dips ahead of major sporting events and anticipated strong earnings, while frustrated investors lament perceived market manipulation and the stock's recent performance.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to investor sentiment being impacted by delays surrounding the Digital Asset Market Clarity Act, affecting crypto-adjacent stocks. While some in the community view this as an overreaction and a buying opportunity, others are questioning Robinhood's ability to diversify its business model with initiatives like banking and prediction markets amidst regulatory headwinds.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending following a significant 10-year data center leasing agreement with AMD, signaling a strategic pivot towards AI and high-performance computing infrastructure. The community is actively discussing this development as a key step in re-rating the company as an infrastructure powerhouse with substantial power capacity, diversifying beyond its traditional Bitcoin mining operations.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is actively trending after its CEO highlighted robust demand for its AI/HPC data centers and confirmed ongoing discussions for new hyperscaler deals at a recent conference. The community views CIFR as a significant long-term play, often citing its power-first colocation model and existing contracts with major tech firms as reasons for substantial future upside. Despite widespread sentiment about market manipulation suppressing its price, investors remain confident in its strategic pivot beyond traditional Bitcoin mining within the expanding AI infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven research firms that are presently covering the stock...

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss.</li><li>The study showed that participants reported reductions in food-related thoughts and cravings</li><li>Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026.</li></ul>Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) surged 36% in premarket trading on Thursday after the company announced encouraging Phase 1a results for CRB-913, an oral CB1 inverse agonist targeting chronic obesity.At the time of writing, <a href="https://stocktwits.com/symbol/CRBP">CRBP</a> was among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Results Of The Study</h2>Corbus Pharma said that the single-and multiple-ascending dose study showed that CRB-913 was safe and well-tolerated across all doses, with no serious treatment-emergent adverse events reported. Gastrointestinal issues were minimal, and daily neuropsychiatric assessments remained negative, indicating no signs of suicidality, depression, or anxiety.Participants reported reductions in food-related thoughts and cravings, highlighting early behavioral effects alongside weight reduction. Pharmacokinetic analysis confirmed that CRB-913 is suitable for once-daily oral dosing.Building on the early results, Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026. This next stage will further explore optimal dosing and continue evaluating safety, tolerability, and efficacy over a longer period.CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. Unlike earlier drugs in this class that raised neuropsychiatric safety concerns, CRB-913 is designed for limited brain penetration to reduce those risks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘extremely’ bullish from ‘neutral’ a day earlier, accompanied by ‘extremely high’ message volumes.One user expressed optimism about the CANYON-1 study.<stembedurl>https://stocktwits.com/LuigiDurante/message/638840548</stembedurl>Year-to-date, the stock has declined nearly 15%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-appears-set-to-retest-200-dma-last-time-it-did-its-rebound-didn-t-endure/cLIxBZBREnI">MSFT Stock Appears Set To Retest 200-DMA – Last Time It Did, Its Rebound Didn’t Endure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal?

Corbus Pharmaceuticals said its Phase 1a study showed CRB-913 was safe and well-tolerated at all doses, with no serious adverse events reported.

Equity

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat...

B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share estimates for Corbus Pharmaceuticals in a report released...

What is B. Riley's Forecast for CRBP FY2029 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors...

Research Analysts Issue Forecasts for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Corbus Pharmaceuticals in a research note issued to investors...

Royal Bank Of Canada Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00

Royal Bank Of Canada reduced their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an "outperform" rating on the stock in a research report on Thursday...

Corbus Pharmaceuticals (NASDAQ:CRBP) Announces Earnings Results, Misses Expectations By $0.10 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.90) EPS for the quarter, missing the consensus...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average rating of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings...

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CRBP
Corbus Pharmaceuticals Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News

CRBPCorbus Pharmaceuticals Holdings Inc